Merck plans to restructure its manufacturing and supply network that will result in the closure of facilities and a workforce reduction, the details of which have not been disclosed. The restructuring is expected to be completed by the end of 2023 with estimated costs between $800 million and $1.2 billion, and charges of approximately $500 million this year. About half of these costs will relate to the closure of facilities and employee severance.  Merck is investing in biologics manufac...